Category: 119-91-5

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.119-91-5,2,2′-Biquinoline,as a common compound, the synthetic route is as follows.

General procedure: To an aqueous solution of terbium nitrate pentahydrate(1.0 mmol, 0.43 g) added an alcoholic solution of ligandHDPBD (3.2 mmol, 0.63 g) dropwise under vigorous stirringon magnetic stirrer. The pH of the resulting mixturewas adjusted to 6.5 with 0.05 M sodium hydroxide solution,resulting in the formation of white precipitates afterconstant stirring for two hours at a temperature of 50-60 C. The precipitates were filtered out and dried inhot air oven to obtained C1 complex.

119-91-5, 119-91-5 2,2′-Biquinoline 8412, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Bala, Manju; Kumar, Satish; Devi, Rekha; Khatkar, Avni; Taxak; Boora, Priti; Khatkar; Journal of Fluorescence; vol. 28; 3; (2018); p. 775 – 784;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.119-91-5,2,2′-Biquinoline,as a common compound, the synthetic route is as follows.

Under argon atmosphere, 1,2-bis(diphenylphosphino)benzene (91.7 mg, 0.205 mmol) was added to 5 mL of the suspension of silver(I) tetrafluoroborate (40.0 mg, 0.205 mmol) in dry dichloromethane, and the mixture was stirred at room temperature for one hour. Then, 2,2′-biquinoline (52.7 mg, 0.205 mmol) was added to the reaction solution, which was stirred at room temperature for another one hour. The pale yellow reaction solution was filtrated, and the filtrate was concentrated, subjected to recrystallization by slow diffusion of chloroform-ether, and dried to provide 171 mg of the pale yellow solid complex. The result of elemental analysis for the obtained complex is shown in Table 2-2, and the composition ratio of the complex was obtained. The present complex corresponds to the above composition formula (5).

119-91-5, 119-91-5 2,2′-Biquinoline 8412, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Sumitomo Chemical Company, Limited; EP2360162; (2011); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

119-91-5, 2,2′-Biquinoline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

1 (0.332 g, 1.0 mmol) and CuI (0.191 g, 1.0 mmol) were dissolved in 5 ml CHCl3. After a few minutes, bq (0.257 g, 1.0 mmol) in 10 ml CHCl3 was added. The mixture was stirred at 40 C for 2 h. After this time, a burgundy solution was formed. Then the solvent was evaporated to dryness. A dark red solid was crystallized from CHCl3 to give microcrystals which are soluble in CHCl3, CH2Cl2, THF, DMSO, CH3CN and CO(CH3)2. Yield 52%. Anal. Calc. for C33H42CuIN5O3P: C, 50.94; H, 5.44; N, 9.00. Found: C, 50.78; H, 6.02; N, 8.91%. MS (CHCl3): 575.1 [Cu(bq)2]+ 100%, 319.0 [Cu(bq)]+ 13%, 650.2 [Cu(bq)1]+ 10%. NMR (298 K, CHCl3) 31P{1H}: -28 s?; 1H: 8.21 s? (H3), 7.95-7.80 (H4 and H7), 7.65-7.55 (H5 and H6), 9.19 s? (H8), 2.78 s (H1-P), 2.40 s? (H2-P), 3.43 s? (H3-P); 13C{1H}:119.39 s (C1, C3), 137.63 s (C4), 128.01 s (C5), 127.53 s (C6), 130.22 s (C7), 130.93 s (C8), 146.42 s (C9), 128.61 s (C10), 55.18 s? (C1-P), 55.57 s (C2-P), 66.74 s (C3-P)., 119-91-5

As the paragraph descriping shows that 119-91-5 is playing an increasingly important role.

Reference£º
Article; Starosta, Rados?aw; Brzuszkiewicz, Anna; Bykowska, Aleksandra; Komarnicka, Urszula K.; Bazanow, Barbara; Florek, Magdalena; Gadza?a, ?ukasz; Jackulak, Natalia; Krol, Jaros?aw; Marycz, Krzysztof; Polyhedron; vol. 50; 1; (2013); p. 481 – 489;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.119-91-5,2,2′-Biquinoline,as a common compound, the synthetic route is as follows.

Example: Zetaeta(NuO3) 2 ¡¤ 6H20 (29.7 mg, 0.1 mmol), 2,2′-biquinoline (25.6 mg, 0.1 mmol), 2,2 -biphenyl diacid (24.0 mg, 0.1 mmol) and NaN3 (13.2 mg, 0.2 mmol), were added to a mixed solvent of 12 mL methanol and secondary deionized water (1:1 volume ratio), It was sealed in a 25 mL stainless steel container lined with tetrafluoroethylene, heated to 140 C for 3 days, and then slowly cooled to room temperature. After filtration, the filter cake was washed with diethyl ether and dried in air to obtain colorless massive crystals, the calculated yield based on Zn(N03)2¡¤6H20 was approximately 61%. This material was insoluble in water and other organic solvents.

119-91-5, As the paragraph descriping shows that 119-91-5 is playing an increasingly important role.

Reference£º
Patent; Anqing Teachers College; Xu Heng; Yan Da; Feng Xuejun; Chen Zhengxiang; Xiong Zhi; Huang Rongyi; (9 pag.)CN108017661; (2018); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.119-91-5,2,2′-Biquinoline,as a common compound, the synthetic route is as follows.

To a solution of cis-[Pt(p-MeC6H4)2(SMe2)2] (0.040 g, 0.078 mmol) in acetone (6 mL) was added a solution of biquinoline (0.020 g, 0.078 mmol) in acetone (6 mL) and the mixture was stirred for 2 h. The solvent was evaporated and a red precipitate product separated and washed twice with n-hexane. Then, the precipitate was dried in vacuum. (Yield: 84%), red, m.p: 160 C (decomp.), Anal. Calc. for [C32H26N2Pt] (1): (M.W: 633.654), C, 60.66; H, 4.14; N, 4.42%. Found: C, 60.09; H, 4.25; N, 4.17%; IR (KBr, y/cm1): (C]C) and (C]N) 1594sh, 1508sh, 1481s, 1431w, (CeH) 815sh, 800s, 746w, (MCl) 509w. 1H NMR (400 MHz, DMSO-d6, d/ppm): 2.17 (6H, s, C6H5CH3), 6.66 (4H, d, 3J(HoHm) 7.60 Hz, 7.23 (d, 4H, 3J(HmHo) 8.00 Hz, 7.29 (3J(PtHo) 17.21 Hz), 8.88 (d, 2H, 3J(H3H4) 8.40 Hz, H3 and H30 of biq), 8.63 (d, 2H, 3J(H4H3) 8.80 Hz, H4 and H40 of biq), 8.33 (dd, 2H, 3J(H8H7) 8.80 Hz, 3J(H8H6) 8.80 Hz, H8 and H80 of biq), 7.86 (d, 2H, 3J(H5H6) 8.00 Hz, H5 and H50 of biq), 7.51 (t, 2H, 3J(H6H5), 3J(H6H7) 16.0 Hz, H6 and H60 of biq). 7.61 (t, 2H, 3J(H7H6), 3J(H7H8) 16.81 Hz, H7 and H70 of biq)., 119-91-5

The synthetic route of 119-91-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Shafaatian, Bita; Heidari, Bahareh; Journal of Organometallic Chemistry; vol. 780; (2015); p. 34 – 42;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.119-91-5,2,2′-Biquinoline,as a common compound, the synthetic route is as follows.

Under argon atmosphere, 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (66.0 mg, 0.114 mmol) was added to 4 mL of the solution of silver(I) tetrafluoroborate (22.2 mg, 0.114 mmol) in dichloromethane, and the mixture was stirred at room temperature for 15 minutes. Then, 2,2′-biquinoline (32.2 mg, 0.125 mmol) was added to the reaction solution, which was heated to reflux with stirring for one hour. The reaction solution was filtrated, and the filtrate was subjected to recrystallization by slow diffusion of dichloromethane-ether and dried to provide 103 mg of the complex of the yellow crystal. [Show Image] The NMR data of the obtained complex is provided below. 1H NMR (300 MHz, CDCl3) delta 8.79 (d, J = 8.7 Hz, 2H), 8.68 (d, J = 8.7 Hz, 2H), 7.92 (d, J = 8.2 Hz, 2H), 7.82 (d, J = 8.2 Hz, 2H), 7.73 (d, J = 6.8 Hz, 2H), 7.48 (t, J = 7.4 Hz, 2H), 7.28-7.23 (m, 6H), 7.13-7.06 (m, 10H), 7.02-6.96 (m, 8H), 6.54-6.50 (m, 2H), 1.85 (s, 6H); 31P NMR (122 MHz, CDCl3) delta -4.6 (d, J (31P-107Ag, 109Ag) = 361, 417Hz). The composition of the obtained complex was determined according to the same method as in Example 15. The present complex corresponds to the above composition formula (5)., 119-91-5

As the paragraph descriping shows that 119-91-5 is playing an increasingly important role.

Reference£º
Patent; Sumitomo Chemical Company, Limited; EP2360162; (2011); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.119-91-5,2,2′-Biquinoline,as a common compound, the synthetic route is as follows.

EXAMPLE 285 2,3-Dihydro-2-[1-[3-phenyl-3-(4-propylphenyl)propyl]-4-piperidinyl]-1H-isoindol-1-one, monohydrochloride STR169 To a suspension of magnesium turnings (1.0 g, 41.2 mmol) in THF (8.2 mL) was added a solution of 1-bromo-4-propylbenzene (Aldrich) (1.64 g, 8.20 mmol) in THF (8.2 mL). The reaction was refluxed for 1.5 h, then cooled to RT. The Grignard solution was cannulated then titrated against 1.0M isopropanol in toluene using 2,2-biquinoline as an indicator to give title compound (0.35M, 70%) as a black solution. STR170 To a solution of Example 284 compound (500 mg, 1.37 mmol) in THF (8 mL) was added dropwise at 0 C. a solution of Part A compound (4.3 mL, 1.51 mmol). The reaction was stirred at 0 C. for 3 h then warmed to RT for 3 h. The reaction was quenched with saturated ammonium chloride solution (3 mL). Ethyl ether (200 mL) was added and the organic was washed with water (2*50 mL), brine (2*50 mL) and dried over MgSO4. Evaporation gave title compound (400 mg, 63%) as a crude oil., 119-91-5

The synthetic route of 119-91-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Bristol-Myers Squibb Company; US5739135; (1998); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI